Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA

Stopped Top line analysis indicated that the study had failed to achieve its primary endpoint.

Conditions

• Myelodysplastic Syndrome
• MDS
• Refractory Anemia With Excess Blasts
• RAEB

Interventions

• DRUG: rigosertib
• DRUG: Any approved or standard-of-care therapy
• DRUG: best supportive care (BSC)
• DRUG: best supportive care (BSC)

Sponsor

Traws Pharma, Inc.